TESARO (TSRO) : Tuesdays money flow indicated an uptick to downtick ratio was at 1.18. The total value of inflow transactions on upticks was $18.53 million, whereas, the total value of outflow trades on downticks was $15.65 million. The total money flow was $2.87 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $3.05 million. The total value of the trades done on upticks was $3.92 million. Downticks saw transactions worth $0.87 million. The total uptick to downtick ratio stood at 4.52, mildly in favor of the bulls. TESARO (TSRO) was trading with a -2.2% change over previous days close. It fell $1.94 during the day and reached $86.26. The stock was -2.75% compared to the previous weeks close.
The company Insiders own 40.5% of TESARO shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of 8.02%. In an insider trading activity, The Securities and Exchange Commission has divulged that Hanke Jeffrey H., Officer (Executive Vp, R&D And Cso) of TESARO, Inc., had unloaded 12,500 shares at an average price of $74.02 in a transaction dated on June 30, 2016. The total value of the transaction was worth $925,250.
Shares of Tesaro, Inc. rose by 2.2% in the last five trading days and 113.83% for the last 4 weeks. Tesaro, Inc. is up 86.15% in the last 3-month period. Year-to-Date the stock performance stands at 64.87%.
TESARO (NASDAQ:TSRO): On Tuesdays trading session , Opening price of the stock was $88.7 with an intraday high of $89.99. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $85.74. However, the stock managed to close at $86.26, a loss of 2.20% for the day. On the previous day, the stock had closed at $88.2. The total traded volume of the day was 777,998 shares.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.